Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
INNOVENT BIO Plans to License PD-1/IL-2 Product IBI363 to Global Pharma Firms: Rumor
Recommend 6 Positive 13 Negative 3 |
||||
|
||||
|
INNOVENT BIO (01801.HK) is working with a consultant to gauge the interest of global pharmaceutical companies in its self-developed pioneered PD-1/IL-2 Alpha-bias bispecific antibodies fusion protein product, IBI363, which it expects to be able to advance its R&D and commercialization by licensing the product to other drug firms, Bloomberg News quoted insiders as saying. INNOVENT BIO is estimated to receive upfront and milestone payments if the license agreement is reached. Sources added that the review is still at a preliminary stage. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
